| Zeit | Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 15.03.23 | Nano Dimension - Creating additive manufacturing industry leader | 599 | Edison Investment Research | Nano Dimension has made a formal, non-binding offer to acquire Stratasys (Nasdaq: SSYS) for US$18.00 per share in cash. Under the terms of the proposal, Nano Dimension, which has been the largest shareholder... ► Artikel lesen | |
| 15.03.23 | Biotech Growth Trust (The) - Keeping the faith in smaller-cap biotech stocks | 288 | Edison Investment Research | The Biotech Growth Trust (BIOG) has been managed by global healthcare specialist OrbiMed Capital since May 2005. During its tenure, the trust has outperformed its benchmark, the NASDAQ Biotechnology... ► Artikel lesen | |
| 15.03.23 | Incannex Healthcare - Encouraging signals from PsiGAD interim review | 525 | Edison Investment Research | Incannex has reported positive interim safety data from its ongoing Phase II PsiGAD study. A review by an independent Data Safety Monitoring Board (DSMB) identified no safety concerns from the first... ► Artikel lesen | |
| 15.03.23 | Sareum Holdings - SDC-1801 trial application refiled in Australia | 319 | Edison Investment Research | Following the protracted stalemate with the UK Medicines and Healthcare products Regulatory Agency (MHRA) for its clinical trial authorisation (CTA) for SDC-1801, Sareum has now announced the filing... ► Artikel lesen | |
| 15.03.23 | Cenkos Securities - Gained market share in tough conditions | 393 | Edison Investment Research | The much-reduced level of capital markets activity in 2022 meant sharply lower profitability for Cenkos, although control over fixed costs and reduced variable compensation provided some mitigation.... ► Artikel lesen | |
| 15.03.23 | 4imprint Group - Brand investment turbocharges growth | 573 | Edison Investment Research | 4imprint's FY22 results are impressive, with 45% organic revenue growth and an uplift in operating margin to 9.0% (FY21: 3.9%) despite some gross margin pressure from inflation. Much of this is due... ► Artikel lesen | |
| 15.03.23 | Actinogen Medical - Getting ready for the next Alzheimer's study | 360 | Edison Investment Research | Actinogen is on track to start US recruitment in Q2 CY23 for the six-month, placebo-controlled Phase IIb portion of the XanaMIA study. The study portion is designed to assess Xanamem in a population... ► Artikel lesen | |
| 15.03.23 | Foxtons Group - New CEO targets recurring income streams | 531 | Edison Investment Research | Foxtons' new CEO has identified historical failings that are expected to be addressed by upgrades to data infrastructure, investment in staff and a reinvigoration of the Foxtons brand. If successful... ► Artikel lesen | |
| 15.03.23 | Premier Miton Global Renewables Trust - Positioned for sector rebound | 368 | Edison Investment Research | The imposition of additional taxes on energy companies by UK and European governments in the last quarter of 2022, together with accompanying anticipation, resulted in a very volatile year for the listed... ► Artikel lesen | |
| 15.03.23 | Centaur Media - Good cash conversion funds further special dividend | 262 | Edison Investment Research | Centaur's FY22 results have come in slightly better than indicated at the year-end update, showing good revenue growth of 6% and a notable step-up in adjusted EBITDA margin, from 16% to 20%, as the... ► Artikel lesen |
| Suchbegriffe der letzen 24 h | Anzahl |
|---|---|
| GAMESTOP | 331 |
| EVOTEC | 299 |
| TUI | 212 |
| NVIDIA | 179 |
| DEUTSCHE BANK | 172 |
| BAYER | 160 |
| PLUG POWER | 145 |
| NEL | 136 |
| RHEINMETALL | 135 |
| SIEMENS ENERGY | 112 |
| BARRICK GOLD | 111 |
| COMMERZBANK | 108 |
| BASF | 106 |
| TESLA | 105 |
| VOLKSWAGEN | 95 |
| RWE | 93 |
| BYD | 89 |
| DEUTSCHE LUFTHANSA | 86 |
| ALLIANZ | 85 |
| RENK GROUP | 81 |
| MERCEDES-BENZ | 79 |
| DEUTSCHE TELEKOM | 78 |
| HEIDELBERGER DRUCK | 76 |
| AIXTRON SE | 74 |
| ALIBABA | 73 |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
